Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection | Zendy

Sharon Walmsley | Zendy; Antonio Antela | Zendy; Nathan Clumeck | Zendy; Dan Duiculescu | Zendy; Andrea Eberhard | Zendy; Félix Gutiérrez | Zendy; Laurent Hocqueloux | Zendy; Franco Maggiolo | Zendy; Uriel Sandkovsky | Zendy; Catherine Granier | Zendy; Keith A. Pappa | Zendy; Brian Wynne | Zendy; Sherene Min | Zendy; Garrett Nichols | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Author(s) -

Sharon Walmsley,

Antonio Antela,

Nathan Clumeck,

Dan Duiculescu,

Andrea Eberhard,

Félix Gutiérrez,

Laurent Hocqueloux,

Franco Maggiolo,

Uriel Sandkovsky,

Catherine Granier,

Keith A. Pappa,

Brian Wynne,

Sherene Min,

Garrett Nichols

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1215541

Subject(s) - dolutegravir , abacavir , medicine , lamivudine , virology , integrase inhibitor , regimen , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , viral load , hepatitis b virus

Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research